The following excerpt is from the company's filing:
Item 5 of the Schedule 13D is amended and restated in its entirety to read as follows:
(a)-(b) The Reporting Person may be deemed to beneficially own 2,464,588 shares of Common Stock. Based on 15,902,949 shares of Common Stock outstanding as of September 19, 2014, such ownership represents 15.2% of the issued and outs tanding shares of the Issuer.
The Reporting Person has (i) sole power to vote 2,464,588 shares of Common Stock which is comprised of 2,164,588 shares and options to purchase 300,000 shares that are vested and exercisable as of September 19, 2014. Such amounts do not include options to purchase 400,000 shares of Common Stock that will not vest within 60 days and therefore are not exercisable within 60 days of the date hereof.
(c) The information included in Item 3 is hereby incorporated by reference. Other than the transactions described in Item 3, the Reporting Person has not engaged in any transaction in the Common Stock during the last 60 days
(d)-(e) Not applicable.
After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
Dated: September 19, 2014
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.
To receive a free e-mail notification whenever ProPhase Labs makes a similar move, sign up!
Other recent filings from the company include the following:
ProPhase Labs's Chief Financial Officer just picked up 360,000 shares - Sept. 15, 2017
Tender offer statement by Issuer - Aug. 25, 2017
Departure of Directors or Certain - Aug. 24, 2017